Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.
Hosted on MSN17h
What's the Better Option for High-Risk Prostate Cancer -- Radiation or Surgery?
Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...
The American Journal of Managed Care22h
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...